The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Derakhshan Behrad since 2023.
This trader's CIK number is 1853109.
At the time of last reporting, Derakhshan Behrad was the Chief Business Officer of Edgewise Therapeutics, Inc.. (stock ticker symbol EWTX).
Also see all insider trading activities at Edgewise Therapeutics, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2025 | EWTX | 0 | $0 | 14,182 | $361,482 | 20,990 | $19,300 |
2024 | EWTX | 0 | $0 | 53,786 | $1,453,897 | 57,276 | $100,491 |
2023 | EWTX | 0 | $0 | 1,747 | $15,557 | 5,208 | $0 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2025-08-12 | EWTX | Option Ex | 5,781 | .00 | 0 |
2025-08-12 | EWTX | Sale | 2,491 | 13.39 | 33,359 |
2025-05-01 | EWTX | Option Ex | 5,209 | .00 | 0 |
2025-05-02 | EWTX | Sale | 1,691 | 16.45 | 27,823 |
2025-02-05 | EWTX | Option Ex | 10,000 | 1.93 | 19,300 |
2025-02-05 | EWTX | Sale | 10,000 | 30.03 | 300,300 |
2024-09-20 | EWTX | Option Ex | 42,068 | 1.93 | 81,191 |
2024-09-20 | EWTX | Sale | 42,068 | 29.03 | 1,221,149 |
2024-05-02 | EWTX | Sale | 1,718 | 18.91 | 32,487 |
2024-05-01 | EWTX | Option Ex | 5,208 | .00 | 0 |
2024-02-07 | EWTX | Option Ex | 600 | 1.93 | 1,158 |
2024-02-08 | EWTX | Option Ex | 4,600 | 1.93 | 8,878 |
2024-02-07 | EWTX | Sale | 600 | 20.00 | 12,000 |
2024-02-09 | EWTX | Option Ex | 4,800 | 1.93 | 9,264 |
2024-02-08 | EWTX | Sale | 4,600 | 20.01 | 92,050 |
2024-02-09 | EWTX | Sale | 4,800 | 20.04 | 96,211 |
2023-05-01 | EWTX | Option Ex | 5,208 | .00 | 0 |
2023-05-02 | EWTX | Sale | 1,747 | 8.90 | 15,557 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Derakhshan Behrad (Chief Business Officer of Edgewise Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.